Fresenius Medical Care

Fresenius Medical Care AG nominates Six Employee Representatives to the Supervisory Board

Retrieved on: 
Monday, February 5, 2024
Supervisory board, Works council, BAD, Supervision, Fresenius Medical Care, Patient, Workforce, FME, IGBCE, Beata, Aktiengesellschaft, Sankt Wendel, Kidney, Woman

BAD HOMBURG, Germany, Feb. 5, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has nominated six employee representatives as members of the company's Supervisory Board.

Key Points: 
  • BAD HOMBURG, Germany, Feb. 5, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has nominated six employee representatives as members of the company's Supervisory Board.
  • Fresenius Medical Care successfully completed its change of legal form into a German stock corporation (Aktiengesellschaft, AG) on November 30, 2023, which also included the formation of a new Supervisory Board, which initially consisted of the six shareholder representatives.
  • The appointed members of the Supervisory Board are:
    Stefanie Balling, Chairwoman of the General Works Council of Fresenius Medical Care in Germany, and Chairwoman of the local works council at the Schweinfurt site (Care Enablement)
    Beate Haßdenteufel, Deputy Chairwoman of the Works Council at the St. Wendel site (Care Enablement)
    Michael Sen, Chairman of the Supervisory Board of Fresenius Medical Care AG, says: "The proposed employee representatives provide a broad range of experience and knowledge to the Supervisory Board.
  • Following the appointment, Fresenius Medical Care is preparing the election of the employee representatives to the Supervisory Board, following legal requirements.

William McKinney Named CEO of Eleanor Health

Retrieved on: 
Tuesday, January 16, 2024
Health Technology, Health, Mental Health, Other Health, Heart, Multimedia, Face, Mental health, WellCare, McKinsey & Company, FMC, Fresenius Medical Care, General partnership, McKinney, Texas, Nursing

Eleanor Health, the first addiction and mental health provider delivering comprehensive, whole-person care through value-based payment models, today announced the appointment of William McKinney as Chief Executive Officer and member of Board of Directors, effective January 9, 2024.

Key Points: 
  • Eleanor Health, the first addiction and mental health provider delivering comprehensive, whole-person care through value-based payment models, today announced the appointment of William McKinney as Chief Executive Officer and member of Board of Directors, effective January 9, 2024.
  • William previously held senior leadership roles at MedSpring Urgent Care and WellCare Health Plans and also consulted for McKinsey & Company.
  • “When you tackle the big issues in healthcare, it’s critical to consider the whole person — physical health, mental health, and social well-being.
  • The trusted relationships Eleanor forms with its members uniquely positions them to coordinate integrated care and address all drivers of health: physical, social and mental.

Sigyn Therapeutics Releases Letter to Shareholders

Retrieved on: 
Thursday, January 4, 2024
Fresenius Medical Care, FDA, Hope, Health, Cancer, Inflammation, Patent, Lipopolysaccharide, Kidney disease, Horizon, Annual report, Death, University, IDE, Letter, Merck, Dialysis, Sepsis, Life, Antibody, Mortality, Therapy, Risk, Toxicity, Patient, Acquisition, AB toxin, ESRD, Hospital, Infection, SAN, DaVita Inc., Community-acquired pneumonia, Horizon Therapeutics, Roivant Sciences, Cardiovascular disease, Security (finance), Pharmaceutical industry

SAN DIEGO, CA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announced the release of a shareholder letter authored by Chairman and Chief Executive Officer, Jim Joyce.

Key Points: 
  • SAN DIEGO, CA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announced the release of a shareholder letter authored by Chairman and Chief Executive Officer, Jim Joyce.
  • The goal of this letter is to help you better understand our opportunities, our challenges, and decision-making processes.
  • In that submission, our endeavors were solely predicated on the development and clinical advancement of Sigyn TherapyTM.
  • This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties.

Micropep Announces Appointment of Jeff Bell as Chief Financial Officer

Retrieved on: 
Tuesday, November 21, 2023
Technology, Agriculture, Other Science, Other Technology, Natural Resources, Research, Green Technology, Artificial Intelligence, Agritech, Environment, Science, Farmer, CFO, Investment, Risk, Fresenius Medical Care, Bell, Management

Micropep Technologies (Micropep), the global leader in micropeptide technology for agricultural applications, today announced the appointment of Jeff Bell as its Chief Financial Officer.

Key Points: 
  • Micropep Technologies (Micropep), the global leader in micropeptide technology for agricultural applications, today announced the appointment of Jeff Bell as its Chief Financial Officer.
  • Bell brings a wealth of experience in bioscience finance and operations to Micropep.
  • He will lead Micropep’s financial planning, analysis, and reporting and will play a vital role in the company’s strategic direction.
  • With over three decades of experience in bioscience finance and operations, I am eager to contribute to the strategic growth and financial strength of Micropep.”

AmeriWater, a Portfolio Company of Edgewater Capital Partners, Appoints Greg Reny as President & CEO

Retrieved on: 
Wednesday, November 29, 2023
Marketing, Kidney, Cantel Medical Corporation, Dialysis, Senior, Fresenius Medical Care, Medtech, Management

Mr. Reny succeeds former CEO, Dennis Mahoney, who will remain on the company's Board of Directors.

Key Points: 
  • Mr. Reny succeeds former CEO, Dennis Mahoney, who will remain on the company's Board of Directors.
  • Mr. Reny is a medical technology executive with 30 years of cross-functional international business leadership experience.
  • He most recently served as Senior Vice President and General Manager of the Renal business unit at STERIS, which was divested by STERIS to Evoqua in 2022.
  • I look forward to connecting with the talented team as we endeavor together towards a very bright and exciting future for the company," said Mr. Reny.

Extracorporeal Membrane Oxygenation Machines Market to grow by USD 243.6 million from 2022 to 2027 | North America to account for 37% of market growth- Technavio

Retrieved on: 
Friday, November 24, 2023
Abbott Laboratories, ECMO, LivaNova, ROW, Laboratory, Research, Otoscope, USD, Medtronic, PMP, Software, Abiomed, Fresenius Medical Care, Growth, Getinge Group, Free, Retail, Sewage treatment, Speciality chemicals

NEW YORK, Nov. 24, 2023 /PRNewswire/ --The extracorporeal membrane oxygenation machines market size is expected to grow by USD 243.6 million from 2022 to 2027.

Key Points: 
  • NEW YORK, Nov. 24, 2023 /PRNewswire/ --The extracorporeal membrane oxygenation machines market size is expected to grow by USD 243.6 million from 2022 to 2027.
  • Extracorporeal Membrane Oxygenation Machines Market: Segmentation Analysis
    The market share growth by the veno-venous segment will be significant during the forecast period.
  • Detailed information on factors that will drive the growth of the extracorporeal membrane oxygenation machines market between 2022 and 2027.
  • Growth of the extracorporeal membrane oxygenation machines market across North America, Europe, Asia, and ROW
    Comprehensive analysis of factors that will challenge the growth of extracorporeal membrane oxygenation machines market companies.

Fresenius Medical Care enters into favorable settlement agreement with U. S. government with positive earnings impact of approx. EUR 175 million - 2023 earnings outlook raised

Retrieved on: 
Tuesday, November 21, 2023
Frankfurt Stock Exchange, FME, Complaint, Kidney, Patient, Fresenius Medical Care, Nature, Element, Dialysis, KPI, Defense, COVID-19, Government, FMS, Pharmaceutical industry, Health insurance, Tricare

Tricare provides reimbursement for dialysis treatments and other medical care provided to members of the military services, their dependents and retirees.

Key Points: 
  • Tricare provides reimbursement for dialysis treatments and other medical care provided to members of the military services, their dependents and retirees.
  • Fresenius Medical Care therefore expects a net positive impact on operating income (guidance basis)1 of approx.
  • As a consequence of the settlement agreement, Fresenius Medical Care today raises its earnings outlook.
  • Through its network of 4,014 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 342,000 patients around the globe.

Fresenius Medical Care appoints Craig Cordola as new Management Board member for Care Delivery

Retrieved on: 
Tuesday, October 31, 2023
Kidney, Knowledge, Frankfurt Stock Exchange, FME, American College, Health administration, Financial Oversight and Management Board for Puerto Rico v. Aurelius Investment, LLC, Organization, Cyprus Securities and Exchange Commission, University of Houston–Clear Lake, Health, MBA, Lanny Cordola, Dialysis, Ascension, Supervisory board, Memorial Hermann Health System, COVID-19, Business administration, Retirement, Fresenius Medical Care, University of Texas at Austin, University, MHA, Master of Business Administration, Patient, FMS, Pharmaceutical industry, Nursing, Psychology

WALTHAM, Mass., Oct. 31, 2023 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has appointed Craig Cordola (52) as new Management Board member for the globally operating Care Delivery segment.

Key Points: 
  • WALTHAM, Mass., Oct. 31, 2023 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has appointed Craig Cordola (52) as new Management Board member for the globally operating Care Delivery segment.
  • Michael Sen, Chairman of the Supervisory Board of Fresenius Medical Care Management AG, said: "We are delighted to have Craig Cordola join the Management Board of Fresenius Medical Care as the leader of the global Care Delivery organization.
  • With this expertise, he will be a crucial player in the Management Board in implementing Fresenius Medical Care's turnaround and focusing on patient care."
  • Craig Cordola said: "I am excited to join Fresenius Medical Care, the global leader in kidney care and leading healthcare brand across this industry.

Fresenius Medical Care Demonstrates Commitment to Innovating Dialysis and Kidney Disease Care with Presentations at the American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on: 
Tuesday, October 31, 2023
Kidney, Frankfurt Stock Exchange, Patient, Hemofiltration, Research, FME, Intelligence, III, HDF, Assessment of kidney function, AVF, Big data, Fatigue, HD, American Society of Nephrology, Saskatchewan River Sturgeon Management Board, Arteriovenous fistula, FX, Health, Society, Artificial intelligence, Dialysis, PO4, PSM, COVID-19, ASN, Machine learning, Congress, Fresenius Medical Care, FKC, RBV, Creatinine, Scientific Committee on Oceanic Research, FMS, Peritoneum, IDS, Data science, Pharmaceutical industry, Medical device, Hemodialysis, Nephrology

Fresenius Medical Care announces presentations at the American Society of Nephrology (ASN) Kidney Week 2023.

Key Points: 
  • Fresenius Medical Care announces presentations at the American Society of Nephrology (ASN) Kidney Week 2023.
  • Scientific and medical experts from across Fresenius Medical Care will present research related to many important topics in kidney disease care.
  • Through its network of 4,050 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 344,000 patients around the globe.
  • Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius Medical Care Achieves Key AI Milestone With First-Phase Completion of Largest Global Dialysis Clinical Dataset

Retrieved on: 
Thursday, October 26, 2023
Cloud, Kidney, Knowledge, Frankfurt Stock Exchange, Global Medical Device Nomenclature, FME, Innovation, HIPAA, Physician, MD, Saskatchewan River Sturgeon Management Board, Doctor of Philosophy, Health, Research, Society, Artificial intelligence, Quality of life, Digital technology, Dialysis, Database, COVID-19, Medicine, Fresenius Medical Care, Kidney disease, Privacy, AI, Patient, FMS, GDPR, Medical imaging, Medical device, Pharmaceutical industry

"The data created across Fresenius Medical Care's global clinical footprint is unmatched in its breadth and depth, and is one of the company's greatest competitive advantages," said Stuart McGuigan, Global Chief Information Officer of Fresenius Medical Care.

Key Points: 
  • "The data created across Fresenius Medical Care's global clinical footprint is unmatched in its breadth and depth, and is one of the company's greatest competitive advantages," said Stuart McGuigan, Global Chief Information Officer of Fresenius Medical Care.
  • Through its network of 4,050 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 344,000 patients around the globe.
  • Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers.
  • Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.